Amarin (AMRN -7.8%) comes under pressure after the FDA's update to its Orange Book gives it's...


Amarin (AMRN -7.8%) comes under pressure after the FDA's update to its Orange Book gives it's fish oil pill Vascepa "no unexpired exclusivity," though no NCE decision was made.

From other sites
Comments (4)
  • twritchie416
    , contributor
    Comments (19) | Send Message
     
    Can't we all agree that the true determinant for the stock is the sales figures for Vascepa. If big pharma hasn't bought AMRN yet, I think they have moved on from NCE status. Companies just want to see how well the product sells.
    18 Jan 2013, 03:29 PM Reply Like
  • Soffie
    , contributor
    Comments (3) | Send Message
     
    Those who only look at the downside are confirmed bears, Those who look at all sides make good decisions. AMRN good side outweighs downside considerably. FDA does not need to buy off on anything that has such tremendous potential. Time will tell.
    19 Jan 2013, 04:34 AM Reply Like
  • j.rogers
    , contributor
    Comments (8) | Send Message
     
    Vascepa is a drug,period! It has been proven effective, it will be prescribed and a degree of sucess will be realized. To what degree will be reflected in the stock price, peroid!! Patience
    21 Jan 2013, 08:27 AM Reply Like
  • magwitch
    , contributor
    Comments (4) | Send Message
     
    fully agree with comments .. Amarin has an excellent future.. but curious as to why FDA would put off NCE decsion... odd
    21 Jan 2013, 09:49 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs